Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series †

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) show meaningful efficacy and tolerability in patients with metastatic breast cancer (MBC), but the optimal sequence of ET has not been established. It is not clear if patients with lobular breast carcinomas (...

Descripción completa

Detalles Bibliográficos
Autores principales: Orlandi, Armando, Iattoni, Elena, Pizzuti, Laura, Fabbri, Agnese, Botticelli, Andrea, Di Dio, Carmela, Palazzo, Antonella, Garufi, Giovanna, Indellicati, Giulia, Alesini, Daniele, Carbognin, Luisa, Paris, Ida, Vaccaro, Angela, Moscetti, Luca, Fabi, Alessandra, Magri, Valentina, Naso, Giuseppe, Cassano, Alessandra, Vici, Patrizia, Giannarelli, Diana, Franceschini, Gianluca, Marchetti, Paolo, Bria, Emilio, Tortora, Giampaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766166/
https://www.ncbi.nlm.nih.gov/pubmed/33353132
http://dx.doi.org/10.3390/jpm10040291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766166/
https://www.ncbi.nlm.nih.gov/pubmed/33353132
http://dx.doi.org/10.3390/jpm10040291

Ejemplares similares